Next Article in Journal
Polish Respiratory Society Guidelines for the Methodology and Interpretation of the 6 Minute Walk Test (6MWT)
Previous Article in Journal
The Statement of the Polish Society of Allergology Experts on the Treatment of Difficult-To-Treat Asthma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
ARM
Volume 83
Issue 4
10.5603/PiAP.2015.0053
arm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Statement of the Polish Society of Allergology Regarding Necessary Changes in Therapeutic Program of Severe IgE-Mediated Allergic Asthma with Omalizumab

by
Zbigniew Bartuzi
1,
Anna Bodzenta-Łukaszyk
2,
Piotr Kuna
3,*,
Izabela Kupryś -Lipińska
3,
Ewa Niżankowska -Mogilnicka
4 and
Bolesław Samoliński
5
1
Department of Allergology, Clinical Immunology and Internal Medicine Collegium Medicum University of Mikołaj Kopernik, Toruń, Poland
2
Department of Allergology and Internal Medicine Medical, Białystok, Poland
3
Department of Internal Medicine, Asthma and Allergy, University Hospital N. Barlicki, ul. 22 Kopcinskiego 22, 90-153 Łódź, Poland
4
Pulmonology Clinic, Jagiellonian University, Collegium Medicum, Kraków, Poland
5
Department of Prophylaxis of Environmental Threats and Allergology, Medical University, Warsaw, Poland
*
Author to whom correspondence should be addressed.
Adv. Respir. Med. 2015, 83(4), 335-338; https://doi.org/10.5603/PiAP.2015.0053
Submission received: 13 June 2015 / Revised: 9 July 2015 / Accepted: 9 July 2015 / Published: 9 July 2015

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

According to the current (2015) recommenda-tions of Global Initiative for Asthma (GINA) dealing under the auspice of World Health Organization (WHO) and in line with registered by EMA in EU as well as in Poland Summary of Product Charac-teristics (SmPC) [...]

Share and Cite

MDPI and ACS Style

Bartuzi, Z.; Bodzenta-Łukaszyk, A.; Kuna, P.; Kupryś -Lipińska, I.; Niżankowska -Mogilnicka, E.; Samoliński, B. The Statement of the Polish Society of Allergology Regarding Necessary Changes in Therapeutic Program of Severe IgE-Mediated Allergic Asthma with Omalizumab. Adv. Respir. Med. 2015, 83, 335-338. https://doi.org/10.5603/PiAP.2015.0053

AMA Style

Bartuzi Z, Bodzenta-Łukaszyk A, Kuna P, Kupryś -Lipińska I, Niżankowska -Mogilnicka E, Samoliński B. The Statement of the Polish Society of Allergology Regarding Necessary Changes in Therapeutic Program of Severe IgE-Mediated Allergic Asthma with Omalizumab. Advances in Respiratory Medicine. 2015; 83(4):335-338. https://doi.org/10.5603/PiAP.2015.0053

Chicago/Turabian Style

Bartuzi, Zbigniew, Anna Bodzenta-Łukaszyk, Piotr Kuna, Izabela Kupryś -Lipińska, Ewa Niżankowska -Mogilnicka, and Bolesław Samoliński. 2015. "The Statement of the Polish Society of Allergology Regarding Necessary Changes in Therapeutic Program of Severe IgE-Mediated Allergic Asthma with Omalizumab" Advances in Respiratory Medicine 83, no. 4: 335-338. https://doi.org/10.5603/PiAP.2015.0053

Article Metrics

Back to TopTop